Surfing prognostic factors in head and neck cancer at the Millennium

被引:39
作者
Chiesa, F [1 ]
Mauri, S
Tradati, N
Calabrese, L
Giugliano, G
Ansarin, M
Andrle, J
Zurrida, S
Orecchia, R
Scully, C
机构
[1] European Inst Oncol, Head & Neck Div, Milan, Italy
[2] European Inst Oncol, Sci Directors Off, Milan, Italy
[3] European Inst Oncol, Div Radiotherapy, Milan, Italy
[4] Univ Milan, Sch Med, Milan, Italy
[5] Univ London Univ Coll, Eastman Dent Inst, London, England
[6] Univ Pavia, ENT Clin, Sch Med, I-27100 Pavia, Italy
[7] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Prague, Czech Republic
关键词
head and neck cancer; prognostic factors; biomarkers; cost analysis; reliability; clinical practice;
D O I
10.1016/S1368-8375(99)00043-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The ability to reliably predict cancer outcome could tailor therapy to the aggressiveness of the tumour to achieve the best results in terms of loco-regional control, overall survival and quality of life. Retrospective and prospective clinical trials involving large series of patients have validated some predictive clinical and pathological factors, whereas the utility of many other prognostic factors has not been established. This has led to some confusion in clinical practice. In order to clarify the significance, role and cost of these prognostic factors we carried out a Medline search of all papers published between 1993 and 1998 concerning the reliability and cost of markers with prognostic significance, in head and neck squamous cell carcinoma, and assessed the results according to a number of criteria relating to reliability and cost. Regarding reliability we classified prognostic factors into: (1) those with a proven significance based on the fact that they were unanimously reported as having an independent statistical correlation with outcome and prognosis; and (2) those for which results were not unanimous, and which significance is still controversial. Cost analysis showed a substantial difference between validated tests which are of low cost and experimental tests which are expensive. Based on these data regarding both the reliability and cost of each prognostic factor, we propose guidelines for their use in clinical practice in the year 2000. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:590 / 596
页数:7
相关论文
共 94 条
  • [1] Akervall JA, 1997, CANCER, V79, P380
  • [2] AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO
  • [3] 2-6
  • [4] Ambrosch P, 1996, EUR ARCH OTO-RHINO-L, V253, P329
  • [5] Arai Yasuhiro, 1997, Auris Nasus Larynx, V24, P193, DOI 10.1016/S0385-8146(96)00018-1
  • [6] Avril M F, 1993, Rev Prat, V43, P594
  • [7] P53 overexpression in head and neck carcinoma and radiotherapy results
    Awwad, S
    Jaros, E
    Somes, J
    Lunec, J
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (02): : 323 - 332
  • [8] SIGNIFICANCE OF TUMOR THICKNESS IN SOFT PALATE CARCINOMA
    BAREDES, S
    LEEMAN, DJ
    CHEN, TS
    MOHITTABATABAI, MA
    [J]. LARYNGOSCOPE, 1993, 103 (04) : 389 - 393
  • [9] PROGNOSTIC-SIGNIFICANCE OF DNA-PLOIDY IN ORAL SQUAMOUS-CELL CARCINOMAS - A RETROSPECTIVE HOW AND IMAGE CYTOMETRIC STUDY WITH COMPARISON OF DNA-PLOIDY IN EXCISIONAL BIOPSY SPECIMENS AND RESECTION SPECIMENS, PRIMARY TUMORS, AND LYMPH-NODE METASTASES
    BARETTON, G
    LI, X
    STOLL, C
    FISCHERBRANDIES, E
    SCHMIDT, M
    LOHRS, U
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1995, 79 (01): : 68 - 76
  • [10] Barzan L, 1996, ARCH OTOLARYNGOL, V122, P1299